David Raben Biography and Net Worth

A board-certified radiation oncologist, Dr. David Raben joins Bicara with more than 25 years of biopharma and academic translational oncology experience, having most recently served as vice president of global product development and product general manager, of oncology, at Amgen.  At Amgen, his work centered on driving the anti-DLL3 program in neuroendocrine cancers. Before that, David served as vice president and franchise leader, of clinical development oncology, at Genentech, focusing on precision medicine and immunotherapy trials in head and neck, thoracic, skin, and rare cancers, in both late-stage and locally advanced settings.

David has spent more than 20 years as a professor and an associate member of the University of Colorado Cancer Center, where his main areas of focus have been evaluating and combining novel biologic therapies in the laboratory and clinical trials for patients with locally advanced cancers of the head and neck and lung. His extensive clinical expertise in the management of head, neck, and thoracic cancers also extends to genitourinary cancers, along with translational experience in areas such as EGFR signaling, DNA damage repair, TGFb, and checkpoint inhibition.

Nationally, David served on the NRG Oncology Head and Neck Cancer (HNC) steering committee for over 15 years and established and led the Radiation Developmental Therapeutics Committee at the NRG. He remains an active member of the American Head and Neck Society, IASLC, ESMO, AACR, and ASTRO. Dr. Raben has authored over 180 publications, 13 book chapters, and his research has been published in high-impact journals including the New England Journal of Medicine, Clinical Cancer Research, Nature Medicine, and Nature Biology Communications.

David holds a Bachelor of Arts degree from Duke University and earned his MD from Wake Forest University.  He completed his residency training in Radiation Oncology at the Johns Hopkins Hospital.